{"disease":{"id":"bladder-cancer-tnm-staging-primary-tumor-t-t2a","name":"bladder cancer tnm staging primary tumor t t2a"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03518320","title":"Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Taris Biomedical LLC","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}